Partners putting the model to work.
We work with therapeutics teams to interrogate disease before the bench does, modelling target biology, patient response, and resistance on real data, so programme decisions are grounded in how the disease actually behaves.
Selected collaborations
Mercury Bio
Mercury Bio develops large-molecule therapeutics for the brain, using its yeast extracellular vesicle (yEV™) platform to carry proteins, RNA, and other biologics into neurons across the blood-brain barrier. In our strategic collaboration, Meta-Flux brings its disease-scale simulation to their neurodegeneration programmes, combining multi-omics and systems-biology modelling to map how neuronal pathways shift in Parkinson’s and Alzheimer’s, and sharpening target selection, pathway prioritisation, and biomarker strategy before the expensive work begins.
Read the announcement
Celtic Biotech
Celtic Biotech develops snake-venom-derived cancer therapeutics; its lead candidate, CB-24 (crotoxin), targets solid tumours where treatment options are limited. Working together with European Innovation Council Access+ support, Meta-Flux profiles CB-24 across 831 oncology cell lines alongside harmonised multi-omics and clinical data, modelling the patterns of sensitivity and resistance that point to the patients most likely to respond, work that feeds patient stratification, clinical development, and regulatory planning.
How AI is accelerating Celtic’s oncology work
Partner with us in modelling the diseases that matter.
Whether you help build the model or put it to work, we’d like to hear from you.